Digg
Del.icio.us
Yahoo
Google
Newsvine
Weekly SCRI Mentions
November 10, 2011
|
Week of 11/4/2011-11/11/2011 |
|
|
|
|
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced 32 abstracts, involving six molecules in the Company’s portfolio, have been accepted for oral presentation at this year’s American Society of Hematology (ASH) annual meeti |
|
StreetInsider | 11/08/11 12:58 |
− Landmark VELCADE five-year follow-up data in previously untreated multiple myeloma to be featured in oral presentation − CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE: 4502) today announced 32 abs
|
Reuters Press Release News Headlines | 11/08/11 12:53 |
More than Thirty Abstracts on VELCADE® and Leading Millennium Pipeline Compounds to be Presented in Oral Sessions at 53rd American Society of Hematology Annual Meeting − Landmark VELCADE five-year follow-up data in previously untreated multiple myeloma to be featured in oral presentation − Millenn
|
News Blaze | 11/08/11 12:49 |
Share With Friends CAMBRIDGE, Mass. - (BUSINESS WIRE) - Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced 32 abstracts, involving six molecules in the Company's portfolio, have been accepted for oral presentation at this
More than Thirty Abstracts on VELCADE(r) and Leading Millennium Pip...
|
Finwin | 11/08/11 12:48 |
Business Editors/Health Editors CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 08, 2011--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced 32 abstracts, involving six molecules in the Company's portfolio, have been accepted for
|
4-Traders | 11/08/11 12:45 |
? Landmark VELCADE five-year follow-up data in previously untreated multiple myeloma to be featured in oral presentation ? Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced 32 abstracts, involving six molecules in the Co
Week of 10/7/2011-10/14/2011
Transforming a diagnosis into inspiration
|
La Junta Tribune-Democrat | 10/14/11 20:15 |
(ARA) - Most people who hear the dreaded words, "You have cancer," immediately feel they have been given a death sentence. Jason Green knows this feeling all too well.
HCA International gets green light for clinical trials from insurers
|
Health Insurance | 10/12/11 07:28 |
Targeted treatment "the future of cancer care" HCA International has secured agreements from Bupa and AXA PPP healthcare to fund policyholders to participate in clinical trials for new drugs.
Targeted drug combo shows promise against melanoma
|
Science Magazine Daily News | 10/11/11 20:51 |
CHICAGO (Reuters) – The combination of two experimental pills developed by GlaxoSmithKline Plc has shown promise as a treatment for melanoma, the most deadly type of skin cancer, according to new research.
Florida Cancer Specialists & Research Institute expands services
|
Daily Commercial | 10/09/11 09:03 |
Florida Cancer Specialists & Research Institute expands services Merger adds 7 clinical sites Florida Cancer Specialists & Research Institute announced that a merger with three oncology/hematology practice groups in Central Florida is now complete.
PERIFOSINE IN COLORECTAL CANCER
|
CANCER AND IMPORTANT MEDICAL NEWS (Blog) | 10/07/11 13:50 |
J Clin Oncol. 2011 Oct 3. [Epub ahead of print] Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer.
Week of September 26-October 2
|
Check Orphan | 09/27/11 07:13 |
|
The Multiple Myeloma Research Foundation (MMRF) today announced that the first patient has enrolled in a landmark 1000-patient study designed to uncover the molecular segments and variations of multiple myeloma. |
|
La Junta Tribune-Democrat | 09/27/11 02:23 |
|||||
|
(ARA) - Most people who hear the dreaded words, "You have cancer," immediately feel they have been given a death sentence. Jason Green knows this feeling all too well.
|
|
|
|
Purpose: The aim of the study was to evaluate the feasibility and efficacy of adding bevacizumab and erlotinib to concurrent chemoradiation therapy for first-line treatment of patients with locally advanced squamous carcinoma of the head and neck. |
|
|
|
NORWALK, Conn. --(Business Wire)-- The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a multi-year collaboration with Millennium: The Takeda Oncology Company to advance the MMRF's emerging research program in personalized medicine. |
|
|
|
The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a multi-year collaboration with Millennium: The Takeda Oncology Company to advance the MMRF?s emerging research program in personalized medicine. |
|
|
|
Purpose: The aim of the study was to evaluate the feasibility and efficacy of adding bevacizumab and erlotinib to concurrent chemoradiation therapy for first-line treatment of patients with locally advanced squamous carcinoma of the head and neck. |
Week of September 19-25
|
The Street | 09/19/11 09:00 |
SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first patient was dosed in the Company's Phase I clinical trial of its lead drug candid
Marshall Edwards (MSHL) Doses First Patient in ME-143 Phase I
|
StreetInsider | 09/19/11 09:03 |
Marshall Edwards, Inc. (Nasdaq: MSHL), reports that the first patient was dosed in the Company's Phase I clinical trial of its lead drug candidate ME-143 in patients with refractory solid tumors.
|
BioSpace | 09/19/11 11:31 |
SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first patient was dosed in the Company's Phase I clinical trial of its lead drug candid
|
Times Leader - mediawebsite.net | 09/19/11 18:52 |
Company to Host Conference Call on Thursday, September 29
...refractory solid tumors. The trial, conducted in collaboration with the Sarah Cannon Research Institute, is expected to enroll up to 24 patients...
Take heart in breast cancer fight
|
The Tennessean | 09/20/11 03:56 |
Drug access, more research resources are saving lives
...tremendous amount of resources into research and development. Locally , Sarah Cannon Research Institute operates the nation s second -largest cancer...
|
Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candi |
|
|
|
|
Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first patient was dosed in the Company's Phase I clinical trial of its lead drug candidate ME-143 in patients with refractory sol
|
Week of September 12-18
Transforming a diagnosis into inspiration
|
The Observer-Dispatch (AP) | 09/18/11 13:32 |
(ARA) - Most people who hear the dreaded words, "You have cancer," immediately feel they have been given a death sentence. Jason Green knows this feeling all too well.
|
Therapeutics Daily | 09/15/11 08:07 |
-- Entinostat in combination with exemestane prolonged progression-free survival -- -- Randomized, placebo-controlled data to be in an oral presentation at ASCO Breast Cancer Symposium 2011 -- Waltham, Mass.
|
|
|
(ARA) - Most people who hear the dreaded words, "You have cancer," immediately feel they have been given a death sentence. Jason Green knows this feeling all too well. |
|
|
|
|
|
|
Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that ENCORE 301, a randomized, placebo-controlled phase 2 study of exemestane with and without entinostat hit its primary endpoint of an improvement in progression-free survival (PFS). |
Our News
View All News-
SCRI in the News
April 12, 2012
-
Nashville woman's cancer fight inspiring thousands
March 26, 2012
NASHVILLE, TN (WSMV) - Her's was a bleak situation. A young Nashville mom's third child was stillborn, then, to make matters worse, the woman was diagnosed with stage four colon cancer.
-
Collaborating to Provide Comprehensive Cancer Care
March 22, 2012
A discussion between primary care providers and the oncology multidisciplinary team” event - also known as Oncology 101. The event is a CME program for Primary Care Physicians and advanced practitioners to learn more about oncology care.